2 weeks Ago By Defense World Staff
Regulus Therapeutics ( NASDAQ:RGLS – Get Free Report ) ‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock.
Other research analysts also recently issued research reports about the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 14th.
StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock.
According to MarketBeat, Regulus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $10.80. Read Our Latest Analysis on Regulus Therapeutics Regulus Therapeutics Price Performance Regulus Therapeutics ( NASDAQ:RGLS – Get Free Report ) last released its earnings results on Thursday, November 7th.
The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.
03). On average, equities analysts expect that Regulus Therapeutics will post -0.8 EPS for the current year.
Institutional Inflows and Outflows Institutional investors have recently modified their holdings of the company. Creative Planning bought a new position in Regulus Therapeutics during the third quarter worth about $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $33,000.
Victory Capital Management Inc. boosted its stake in shares of Regulus Therapeutics by 10.4% during the 3rd quarter.
Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after acquiring an additional 37,480 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Regulus Therapeutics by 56.
4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in Regulus Therapeutics in the 2nd quarter valued at $136,000.
92.38% of the stock is currently owned by institutional investors and hedge funds. Regulus Therapeutics Company Profile ( Get Free Report ) Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. Further Reading Five stocks we like better than Regulus Therapeutics Stock Average Calculator Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025 How to Choose Top Rated Stocks Is Tesla’s Valuation a Bubble or Backed by Real Growth? How to Know if a Stock Pays Dividends and When They Are Paid Out Trucking Stocks Led the Pack Last Week: Can They Keep Rolling? Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
